Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Strategy Inc. (MSTR) vs Tilray Brands Inc (TLRY) Price & Performance

Strategy Inc.Trade
Tilray Brands IncTrade

Price performance (Past 24H)

Key statistics

Strategy Inc. vs Tilray Brands Inc — how do they compare? Strategy Inc. trades at $132.9 (market cap $54.24B), while Tilray Brands Inc trades at $4.21 (market cap $591.60M). The key difference: Strategy Inc. is far larger — about 91.7× Tilray Brands Inc's market cap, and Strategy Inc. is trading nearer its 52-week high, Tilray Brands Inc nearer its low. Which is the better fit depends on your goals.

MSTRTLRY
Market Cap
$54.24B$591.60M
Sector
TechnologyHealth
52-Week High
$359.69$21.00
52-Week Low
$82.31$3.88
Enterprise Value
$73.00B$758.73M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Strategy Inc.

MSTR trades at $136.52, down 4.4% on the day, with a bullish technical signal from moving averages. The company reported Q2 2026 EPS of -$24.45, missing estimates, and has a negative net income margin of -6,102.96%. Recent news highlights a $176.3 million preferred stock buyback instead of Bitcoin purchases, and a partnership with Google Cloud for an AI forum series.

The outlook is mixed: analyst consensus is bullish with a $229.64 price target, but significant risks include persistent earnings misses, high debt, and negative profitability. The stock's performance is heavily tied to Bitcoin market sentiment, posing volatility risks despite institutional interest.

Tilray Brands Inc

TLRY trades at $4.30, down 4.44% today, reflecting ongoing investor skepticism despite record fiscal 2026 revenue of $915 million. The stock shows bearish technical signals with key support at $4.00, while fundamentals reveal significant challenges including negative net income margins (-13.26%) and consecutive earnings misses. Recent developments include strategic partnerships expansion in New York and California spirits markets and increased medical cannabis production capacity to 275 metric tonnes.

TLRY faces substantial execution risks with persistent losses and negative cash flow, though trading below book value (P/B 0.37) offers potential value. Analyst consensus remains cautious with 65% hold ratings, while regulatory progress in cannabis remains a key catalyst. The stock requires successful margin improvement and U.S. regulatory clarity for sustained recovery.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Strategy Inc.

MicroStrategy Inc is a provider of enterprise analytics and mobility software. It offers MicroStrategy Analytics platform that delivers reports and dashboards and enables users to conduct ad hoc analysis and share insights through mobile devices or the Web

Read more on MSTR

About Tilray Brands Inc

Tilray is a Canadian company that grows and sells medical and recreational cannabis. In 2021, Aphria acquired Tilray in a reverse merger and adopted the Tilray name. Most of its sales come from Canada and international medical cannabis exports, while its U.S. business focuses on CBD products and alcohol.

Read more on TLRY